Skip to Main Content

Author Details

Amanda Winters
University of Colorado School of Medicine
2008
30
14
PMIDPaper TitleJournal TitlePublished Year
37584293Molecular measurable residual disease: staring at red herrings.Haematologica2024
36253252Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products.Cytotherapy2023
37873284Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium.bioRxiv2023
37051756Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.Haematologica2023
37036272Identifying patterns of neurocognitive dysfunction through direct comparison of children with leukemia, central nervous system tumors, and sickle cell disease.Pediatr Blood Cancer2023
37358260A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy.Cancer Discov2023
36496523Time to transplantation and pediatric acute myeloid leukemia outcomes.Bone Marrow Transplant2023
34525179The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation.Blood2022
35902048Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.Transplant Cell Ther2022
35218117N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL).Genes Chromosomes Cancer2022
34962700Importance of clinical correlation in the diagnosis of pediatric B-cell lymphomas.Pediatr Blood Cancer2022
34645926Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.Bone Marrow Transplant2022
33375853The propriety of upgrading responses to venetoclaxâ¿¿+â¿¿azacitidine in newly diagnosed patients with acute myeloid leukemia.Leuk Lymphoma2021
34610123Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.Blood Adv2021
32735397Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.Pediatr Blood Cancer2020
33884374Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.Nat Cancer2020
31974170Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.Cancer Discov2020
32822582Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.Cell Stem Cell2020
31136781CD123 CAR T cells for the treatment of myelodysplastic syndrome.Exp Hematol2019
31808875Moving immunotherapy into the front line in ALL.Hematology Am Soc Hematol Educ Program2019
31648312Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.Blood Adv2019
31009835Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.Leuk Res2019
30420752Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.Nat Med2018
30209285Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.Nat Commun2018
30270124Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells.Cancer Cell2018
28548697Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1.Pediatr Blood Cancer2017
28232907MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Front Pediatr2017
21054209A postmenopausal woman with gross cystic disease fluid protein-15 and estrogen receptor-positive recurrence of papillary thyroid cancer.Thyroid2010
19232721Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.Leuk Res2009
17875318The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.Leuk Res2008
  • 1 - 30 of 30

Recommended Authors

Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 0
Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 4
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 5
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Prapti Patel
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 2
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 4
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 0
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 1
Kara L Davis
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 0
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 1
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 4
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 5
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 4
Todd A Alonzo
Keck School of Medicine, University of Southern California
Career Start Year 1999
Number of shared co-authors 1
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 4
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 4
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 0
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 2
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 4
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 2
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 1
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 2
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 0
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Career Start Year 1982
Number of shared co-authors 3
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 1

Collaborators

Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 18
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 17
Brett M Stevens
University of Colorado School of Medicine
Co-authored papers 14
Clayton A Smith
University of Colorado, Aurora CO.
Co-authored papers 12
Diana Abbott
Center for Innovative Design and Analysis, University of Colorado, Aurora CO.
Co-authored papers 11
Mohammad Minhajuddin
University of Colorado School of Medicine
Co-authored papers 10
Shanshan Pei
Zhejiang University Medical Center
Co-authored papers 9
Maria Amaya
University of Colorado School of Medicine
Co-authored papers 8
Courtney L Jones
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Anna Krug
University of Colorado School of Medicine
Co-authored papers 5
Haobin Ye
Institute of Metabolism & Integrative Biology, Fudan University
Co-authored papers 5
Anagha Inguva
University of Colorado School of Medicine
Co-authored papers 4
Travis Nemkov
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Rachel Culp-Hill
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Biniam Adane
The Broad Institute of MIT and Harvard
Co-authored papers 2
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Co-authored papers 2
Fabia Gamboni
University of Colorado Anschutz Medical Campus
Co-authored papers 2
Leylah M Drusbosky
College of Medicine, University of Florida
Co-authored papers 1
Taher Abbasi
Cellworks Group Inc.
Co-authored papers 1
James DeGregori
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Anat Stemmer-Rachamimov
Massachusetts General Hospital
Co-authored papers 1
Sarah Gehrke
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Maura Gasparetto
University of Colorado School of Medicine
Co-authored papers 1
Julie A Reisz
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Tonya Brunetti
Co-authored papers 1
Annika Gustafson
University of Colorado Denver
Co-authored papers 1
Christopher R Cogle
College of Medicine, University of Florida
Co-authored papers 1
Shireen Vali
Cellworks Group Inc.
Co-authored papers 1
Sweta B Patel
The University of Alabama at Birmingham School of Medicine
Co-authored papers 1
Release 1.2